Status: Recruiting
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18-85Biological sex: AllType: InterventionalSponsor: CERo Therapeutics Holdings, Inc.Updated: Mar 27, 2026Locations: 4
Eligibility criteria
Patients need to have a confirmed diagnosis of de novo or secondary AML, or myel... [+2]
Prior therapy with a permanently integrated, genetically modified cell product. [+5]